Clinical Trial Update: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating isatuximab in combination with belantamab mafodotin, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma; recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING